RE:UBSJust a quick follow-up. From a volume standpoint, Taimed - which owns Ibalizumab - has their stock listed in Taiwan, in which Ibalizumab is their flagship product. Their stock trades at $200 Taiwanese Dollars per share, equivalent to about $8 Canadian Dollars per share. Their volume is about 3 Million Shares per day, or about $24 Million Dollars Canadian per day, or about 1.2% of their outstanding shares. If Thera traded 1.2% of their outstanding shares daily, it would represent approximately 780,000 shares per day, on a regular day. On a separate note, Taimed likely has to pay Genentech a royalty of Ibalizumab sales - but Thera does not. Taimed is leveraging Thera because of their specialty in HIV within the US market. Taimed has other territories to consider as well, and thus is not interested in the sales game. Taimed is focused on research - and it is clear that they have strong support from the financial community and their own government.